PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Cited by 13 Publications

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Oncogene, 2019, 38(35):6270-6282

PubMed: 31316145 ( click the link to review the publication )

Platelets, 2019, 30(2):241-250

PubMed: 29257917 ( click the link to review the publication )

Nutr Metab (Lond), 2018, 10.1186/s12986-018-0268-9

PubMed: 29743930 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2553

PubMed: 28079897 ( click the link to review the publication )

Front Immunol, 2017, 7:685

PubMed: 28138329 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9163-74

PubMed: 26824321 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(3):799-809

PubMed: 25573956 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Cell Immunol, 2015, 298(1-2):9-17

PubMed: 26302934 ( click the link to review the publication )

PLoS One, 2014, 9(2):e90388

PubMed: 24587347 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3145-58

PubMed: 24762669 ( click the link to review the publication )

5 Customer Reviews

After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.
(F) EGR-2 and GFI-1 abundance (n = 5).

Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.
Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.
C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.
Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BHT-101	NFPjSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzkb4RnUUN3ME2wMlgzODJ2IN88US=>	M37S[nNCVkeHUh?=
UACC-893	NF3nW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTVwMUm4PFYh\|ryP	NIj3OXBUSU6JRWK=
A427	NUnFWZBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfsTWM2OD13LkeyOVY4KM7:TR?=	M3fTNnNCVkeHUh?=
OCUB-M	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\BZWlEPTB;Nj62OlExOiEQvF2=	MVHTRW5ITVJ?
SW684	M4fBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTdwNUKyOlgh\|ryP	NIDIUZVUSU6JRWK=
SK-LMS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLLTWM2OD17LkCxN\|AzKM7:TR?=	MXLTRW5ITVJ?
CP50-MEL-B	M4PibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XlOmlEPTB;OT6zNFQyQSEQvF2=	MWXTRW5ITVJ?
NCI-H1651	NEi2dHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTBTWM2OD1zMD6wNlc3KM7:TR?=	NIDSd2VUSU6JRWK=
ABC-1	M4TBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTFyLkGwN\|ch\|ryP	MnTaV2FPT0WU
OE19	M33Wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfYc2RKSzVyPUGwMlE4OzNizszN	MoDEV2FPT0WU
DSH1	NGLuNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInNfFlKSzVyPUGwMlg5PzlizszN	NIPhWY9USU6JRWK=
SW13	M2DFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlyzTWM2OD1zMT65N\|E6KM7:TR?=	MXrTRW5ITVJ?
MDA-MB-453	NGDufIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nFWWlEPTB;MUKuNVYxOyEQvF2=	M13PUXNCVkeHUh?=
647-V	NFzIPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVribnZCUUN3ME2xNk4{PTh{IN88US=>	M1:0W3NCVkeHUh?=
NCI-H2342	M4LoSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NES1fHdKSzVyPUGyMlM6QTVizszN	M4LpXnNCVkeHUh?=
LB2241-RCC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXYW4FQUUN3ME2xNk42Pzd7IN88US=>	MV\TRW5ITVJ?
UACC-257	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjVcGtKSzVyPUGzMlQ1PTNizszN	MVfTRW5ITVJ?
NCI-H661	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXTO4tKSzVyPUGzMlY1PDlizszN	MXjTRW5ITVJ?
FADU	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoGwTWM2OD1zMz62PVkzKM7:TR?=	MUHTRW5ITVJ?
A2780	NHSwT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XhNWlEPTB;MUOuPFA1OSEQvF2=	MVLTRW5ITVJ?
NCI-H1793	NImzRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTYTWM2OD1zND60NFg2KM7:TR?=	MkO3V2FPT0WU
TE-8	NWXTXmVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXyNGtKSzVyPUG1MlM1PjVizszN	NFzFUYlUSU6JRWK=
HGC-27	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTF4LkG2OFQh\|ryP	NF7IOHpUSU6JRWK=
MMAC-SF	NH25emFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3S1W2lEPTB;MUeuN\|czPyEQvF2=	NEO5dJZUSU6JRWK=
Calu-6	NIezc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXpfIRpUUN3ME2xPE4yPTF\|IN88US=>	MVLTRW5ITVJ?
HUTU-80	NIXwbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1[3NmlEPTB;MUiuN\|k2QSEQvF2=	NGjwe5ZUSU6JRWK=
SAS	M1nr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn33TWM2OD1zOD62OFU2KM7:TR?=	MX7TRW5ITVJ?
IST-MES1	NYrnT3l{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTtTWM2OD1zOD62OVA5KM7:TR?=	MmDEV2FPT0WU
C3A	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWn2fYI4UUN3ME2xPE44QTF7IN88US=>	MYDTRW5ITVJ?
ES3	NXLFPG5zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFKzdW1KSzVyPUG4Mlg{PjRizszN	MlS2V2FPT0WU
HSC-2	M3\2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\X[2h4UUN3ME2xPU43PTRzIN88US=>	M4PQRXNCVkeHUh?=
T47D	M1vEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPN[nRmUUN3ME2yNE4yPDh3IN88US=>	M4rRXHNCVkeHUh?=
EW-7	MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTJyLki1PFgh\|ryP	MU\TRW5ITVJ?
LN-405	NVnU[\|BPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfKdY9KSzVyPUKwMlg6PjVizszN	MWjTRW5ITVJ?
U031	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonkTWM2OD1{MT60PFAzKM7:TR?=	MX;TRW5ITVJ?
A549	NGXzUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3q3RWlEPTB;MkGuPFQ6OSEQvF2=	MUjTRW5ITVJ?
RMG-I	MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jPVGlEPTB;MkKuNlY3QCEQvF2=	MoC2V2FPT0WU
BT-474	M3X4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\Bc2ZKSzVyPUKyMlY2PTFizszN	MVPTRW5ITVJ?
NB69	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTJ\|LkG1NkDPxE1?	M{T1N3NCVkeHUh?=
NB7	M1\CNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPrOG41UUN3ME2yOE4yQDhizszN	NH:5UWNUSU6JRWK=
HCC1569	M1;LRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1j3dWlEPTB;MkSuOlEzPSEQvF2=	MorxV2FPT0WU
MEL-JUSO	Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDHTWM2OD1{ND62PVA5KM7:TR?=	MV\TRW5ITVJ?
MDA-MB-175-VII	NFrlXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTJ3LkK1NVch\|ryP	NGXneGxUSU6JRWK=
HCC1419	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTJ3Lk[wNFMh\|ryP	M1rQZnNCVkeHUh?=
Ca9-22	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\6OWJKSzVyPUK1MlY1OzJizszN	MYfTRW5ITVJ?
KGN	Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nM[WlEPTB;MkWuO\|U1PyEQvF2=	M2f3[XNCVkeHUh?=
LB373-MEL-D	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\OUphRUUN3ME2yOk4yQTN6IN88US=>	NHz3cpFUSU6JRWK=
NCI-H1755	NWDZSFFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLLdGFkUUN3ME2yOk45QDRzIN88US=>	MlWzV2FPT0WU
D-423MG	M1znb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;VXVJzUUN3ME2yO{4xPzF3IN88US=>	MVPTRW5ITVJ?
DK-MG	NFG1RnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2L4O2lEPTB;MkiuO\|g1PiEQvF2=	M1;menNCVkeHUh?=
NCI-H1623	M1nMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTJ6LkizOFIh\|ryP	NVTFO2w3W0GQR1XS
KU-19-19	NVnPSWhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17aUmlEPTB;MkiuPVk2KM7:TR?=	Ml[zV2FPT0WU
C-33-A	M{HzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTJ7LkKxPVgh\|ryP	NIHNVpZUSU6JRWK=
SCC-4	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTNyLkOzOVQh\|ryP	NF33ZVRUSU6JRWK=
MG-63	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PUcGlEPTB;M{CuOVk6PCEQvF2=	NHXV[YpUSU6JRWK=
LNCaP-Clone-FGC	NF\1eYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XUUGlEPTB;M{GuOFkzOSEQvF2=	NGS1N2xUSU6JRWK=
CAPAN-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTNzLkWyPFYh\|ryP	M2fZfHNCVkeHUh?=
GI-ME-N	M3rZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{D2TGlEPTB;M{GuOVM2OyEQvF2=	NYnIVnpjW0GQR1XS
RERF-LC-MS	NUfYTnVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4f2S2lEPTB;M{KuOlc1PyEQvF2=	MkTYV2FPT0WU
KLE	NXHPVoYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rCeGlEPTB;M{OuOFM{PCEQvF2=	MYjTRW5ITVJ?
KNS-81-FD	Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rpNmlEPTB;M{OuOVAxQCEQvF2=	NGGwdlFUSU6JRWK=
DOK	M3u0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWm3Z5ZJUUN3ME2zOE43PjF{IN88US=>	MV;TRW5ITVJ?
ACHN	M3jvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPSTY9[UUN3ME2zOU4yPTh6IN88US=>	MWfTRW5ITVJ?
KYSE-520	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPNUJNKSzVyPUO1MlI{PjFizszN	MV7TRW5ITVJ?
SBC-5	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1i4R2lEPTB;M{WuOVEyPiEQvF2=	MnfZV2FPT0WU
NCI-H28	NFzSbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH23dXFKSzVyPUO1MlY3QTVizszN	M3\od3NCVkeHUh?=
ES7	NIjSe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPoTWM2OD1\|Nj6yNlQ6KM7:TR?=	M1TrOXNCVkeHUh?=
A172	M1v6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUSzPXF4UUN3ME2zOk41OTh5IN88US=>	NY\ofmtIW0GQR1XS
UM-UC-3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTN5Lki3OFYh\|ryP	NYLMb4pLW0GQR1XS
LXF-289	NGDiUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTN6LkCwOFch\|ryP	MknwV2FPT0WU
KP-4	M2rBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTN6LkS3N\|kh\|ryP	MoTLV2FPT0WU
TE-1	NVTlSHdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M134RmlEPTB;M{muOlU5QSEQvF2=	MnrQV2FPT0WU
G-402	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fYdmlEPTB;NECuNFYyKM7:TR?=	M3vRVHNCVkeHUh?=
786-0	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7KVFJKSzVyPUSwMlkxQTZizszN	MVHTRW5ITVJ?
K5	NG\rdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\pZ\|hKSzVyPUSxMlM3QDZizszN	M37x[HNCVkeHUh?=
SK-N-DZ	MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHwNoVKSzVyPUSxMlM5OjNizszN	M3fheXNCVkeHUh?=
OVCAR-4	Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[0fVJ{UUN3ME20NU44PTZ6IN88US=>	MUHTRW5ITVJ?
T84	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTR{LkGyOlMh\|ryP	NFXGWGVUSU6JRWK=
GCIY	NVnaW4xDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fVdWlEPTB;NEOuNFgxOyEQvF2=	M3q4RnNCVkeHUh?=
BB49-HNC	NXTWZVBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXUSVZKSzVyPUSzMlM{PDhizszN	MlvYV2FPT0WU
SNU-C2B	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTR\|Lk[0N\|Yh\|ryP	MofHV2FPT0WU
TE-6	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzpTWM2OD12Mz64PFk1KM7:TR?=	M4DRTXNCVkeHUh?=
23132-87	M3zsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTR2LkK5O\|gh\|ryP	M1v1XXNCVkeHUh?=
DMS-53	NYXlb3NTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonETWM2OD12ND6zN\|g1KM7:TR?=	MkX4V2FPT0WU
ONS-76	NETiWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rpfWlEPTB;NESuO\|Y3OSEQvF2=	MWTTRW5ITVJ?
DMS-273	MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTR2Lkm0N{DPxE1?	NUHpTXV{W0GQR1XS
COLO-824	M4TxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:1UItKSzVyPUS1Mlg4PzVizszN	NXHHSW1uW0GQR1XS
DMS-114	NF;COo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3L6NWlEPTB;NEWuPFkzPyEQvF2=	MX\TRW5ITVJ?
YKG-1	NHLudXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLoTWM2OD12Nj6wN\|U2KM7:TR?=	MonWV2FPT0WU
RH-18	NHOyPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDSTWM2OD12Nj6zO\|M{KM7:TR?=	M2nIdnNCVkeHUh?=
NCI-H1355	NVjKUZhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LlXmlEPTB;NE[uOlE5KM7:TR?=	MmW5V2FPT0WU
NCI-H2170	NX;F[lhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rNeWlEPTB;NEeuO\|U5PCEQvF2=	NWiyWldlW0GQR1XS
OC-314	M4W3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;lPXNKSzVyPUS3Mlg1PzhizszN	NUHvUVRFW0GQR1XS
NCI-H2030	NVzEXJRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGmxO\|hKSzVyPUS3Mlg6ODZizszN	M2HRRnNCVkeHUh?=
22RV1	NWfBO4Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M133ZWlEPTB;NEeuPVAyPSEQvF2=	M2jieXNCVkeHUh?=
G-401	NGC5TnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTR6LkS0NVUh\|ryP	NUDLboRDW0GQR1XS
YAPC	NGDMSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzjellKSzVyPUS5MlgxPzNizszN	NVXlOY94W0GQR1XS
SW1573	NF34OHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDCTWM2OD13MD6yOFM2KM7:TR?=	NGS0fnJUSU6JRWK=
COLO-792	M2rtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHqxbpdKSzVyPUWwMlYzOzdizszN	MmfCV2FPT0WU
KNS-62	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rheWlEPTB;NUCuO\|UxQCEQvF2=	MkfqV2FPT0WU
NB5	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TufGlEPTB;NUGuOFUxQSEQvF2=	NX\qd5V{W0GQR1XS
CP66-MEL	NFjBNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTBUYxRUUN3ME21NU43PDB6IN88US=>	NHO3S3BUSU6JRWK=
CaR-1	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVi2Nlg2UUN3ME21Nk4xPjB4IN88US=>	NGPQcFNUSU6JRWK=
CAL-54	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjhSnIyUUN3ME21Nk4yOTB{IN88US=>	M4XadXNCVkeHUh?=
8305C	Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\vTWM2OD13Mj6zNVUh\|ryP	M2jmcXNCVkeHUh?=
Calu-3	NUT6OHNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\4TWM2OD13Mj6zO\|M{KM7:TR?=	M3f4O3NCVkeHUh?=
AU565	M{f1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3u1eWlEPTB;NUKuOVUxQSEQvF2=	MVzTRW5ITVJ?
CW-2	MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTV{Lki2OVQh\|ryP	NEfFe2xUSU6JRWK=
BEN	M3nsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHyTWM2OD13Mz63PFYzKM7:TR?=	NYO5VWEyW0GQR1XS
NCI-H1975	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTV\|Lki5OlYh\|ryP	M1fCXHNCVkeHUh?=
HCT-116	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXYNJBRUUN3ME21OE4xOzJ5IN88US=>	M3XnUXNCVkeHUh?=
SH-4	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\ITWM2OD13ND6xN\|gh\|ryP	MV3TRW5ITVJ?
NCI-H1693	M3TnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTV2LkKxNFMh\|ryP	MVXTRW5ITVJ?
BPH-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX72OJhnUUN3ME21OU4zQDl{IN88US=>	M3eyPXNCVkeHUh?=
CAMA-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGr6[HJKSzVyPUW1MlgyOTZizszN	M3nwXHNCVkeHUh?=
A388	NF[zNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\UTWM2OD13Nj6wPVg2KM7:TR?=	MoP2V2FPT0WU
C2BBe1	NYHpN4FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTV4LkK2N\|Qh\|ryP	NIPMWJJUSU6JRWK=
GAMG	NF22NZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTV4LkW5OVUh\|ryP	MUPTRW5ITVJ?
MKN28	NHfsZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvVTWM2OD13Nj64NFE{KM7:TR?=	MYHTRW5ITVJ?
VA-ES-BJ	NEPYOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIO0T3FKSzVyPUW2Mlg4PDVizszN	MVrTRW5ITVJ?
HuCCT1	M3zMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LFNWlEPTB;NUeuNFQ6OiEQvF2=	NHHkWldUSU6JRWK=
BFTC-905	NHe2cnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTV5LkK4PVgh\|ryP	MYPTRW5ITVJ?
LS-123	NH;iZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LKbWlEPTB;NUeuOVY3QCEQvF2=	MVjTRW5ITVJ?
LB996-RCC	M3P2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTV6LkCyPFch\|ryP	MYfTRW5ITVJ?
NCI-H1048	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjzTWM2OD13OD6yNVg5KM7:TR?=	MYrTRW5ITVJ?
COR-L105	NETZeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17aZWlEPTB;NUiuO\|M{PyEQvF2=	NUfGV2tmW0GQR1XS
OVCAR-8	M1fkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmL3TWM2OD13OT6xO\|E3KM7:TR?=	M{PkdXNCVkeHUh?=
SK-N-FI	M4fOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\vTWM2OD13OT6zNlA4KM7:TR?=	NVS0Xmp[W0GQR1XS
MES-SA	MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\sTWM2OD13OT60OVA6KM7:TR?=	MmfXV2FPT0WU
SCC-9	NYHEOGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTV7LkS3OVMh\|ryP	MmX4V2FPT0WU
EFO-27	Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWqyO5VRUUN3ME21PU46PDNizszN	MorYV2FPT0WU
GT3TKB	NXHHW5hCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3O5SmlEPTB;NkCuOlA1QCEQvF2=	MkTsV2FPT0WU
HCC38	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHOT3FyUUN3ME22NU41Ozd7IN88US=>	MnrHV2FPT0WU
MLMA	MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XQO2lEPTB;NkGuOlE3OyEQvF2=	NVniOIw1W0GQR1XS
D-566MG	NV3XWphlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnJUIZPUUN3ME22N{42OjJ2IN88US=>	NYX1[nlJW0GQR1XS
SF295	NFj2fopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHGTWM2OD14Mz62OlU2KM7:TR?=	NHXR[YtUSU6JRWK=
ES4	NIXpWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTZ2LkS3NVkh\|ryP	M1rhd3NCVkeHUh?=
CAKI-1	NFLWNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ezN2lEPTB;NkSuOVczOSEQvF2=	MXHTRW5ITVJ?
OAW-28	NGnK[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDX[JlKSzVyPU[0Mlk3PDdizszN	MkX5V2FPT0WU
NCI-H460	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTZ3LkC4PVch\|ryP	NWi3TIVlW0GQR1XS
JAR	NUDpelBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLJeG9KSzVyPU[1MlU2OTZizszN	NYK4OWcxW0GQR1XS
SNU-449	NIjqbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfa[2FJUUN3ME22OU44PjF4IN88US=>	M3ntTnNCVkeHUh?=
D-392MG	NV\1SGRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYCx[VVwUUN3ME22OU46PDN2IN88US=>	M1HF[3NCVkeHUh?=
EW-22	M4C2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYf5TJFXUUN3ME22Ok4{QTVizszN	MmHUV2FPT0WU
GCT	M33Sc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTZ5LkC0OFMh\|ryP	M{O4TnNCVkeHUh?=
NOS-1	NV:3R5ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTZ5Lk[4Olch\|ryP	M4PZO3NCVkeHUh?=
RH-1	M2fqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGn5eZVKSzVyPU[4MlU2PTlizszN	MV3TRW5ITVJ?
HuH-7	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTZ7LkGwNFIh\|ryP	NVn0OJZJW0GQR1XS
NUGC-3	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fpbGlEPTB;N{CuPVY1PCEQvF2=	MXfTRW5ITVJ?
IST-SL1	NX3vfpdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnzVWVKSzVyPUexMlI{OjRizszN	NEHEUpNUSU6JRWK=
SHP-77	NVzMUmZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTd{LkGxPUDPxE1?	MlTHV2FPT0WU
SW1116	NYHyflZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTd{LkG0NFch\|ryP	Mn7BV2FPT0WU
LK-2	NWL5dZFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\yTWM2OD15Mj64OlEzKM7:TR?=	MorCV2FPT0WU
U-2-OS	MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTpfWZKSzVyPUezMlE5OjhizszN	M{HZWXNCVkeHUh?=
KYSE-150	M2fwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\2TWlEPTB;N{OuOlEyQCEQvF2=	NV70XVBIW0GQR1XS
U251	NFKxO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\Bb2JlUUN3ME23N{45OTZ6IN88US=>	M1jDcnNCVkeHUh?=
HT-1080	NV7EW3hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfK[FRRUUN3ME23OE4zPTd2IN88US=>	NUO3N2tsW0GQR1XS
NCI-H1437	NGf6[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTd2Lk[zNlYh\|ryP	MVHTRW5ITVJ?
HPAF-II	NWqwfWhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTd2Lk[0NVUh\|ryP	MVTTRW5ITVJ?
Becker	Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrhXHNMUUN3ME23OU4yOTB3IN88US=>	M2TQWXNCVkeHUh?=
PANC-10-05	M3vxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGS2TIlKSzVyPUe1MlI5PjVizszN	MkjEV2FPT0WU
TYK-nu	NF3XWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLCTWM2OD15NT6zNVAzKM7:TR?=	MVjTRW5ITVJ?
SKG-IIIa	NHriPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fWV2lEPTB;N{WuN\|M1OSEQvF2=	MnXZV2FPT0WU
NCI-H1993	MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml20TWM2OD15NT63N\|k4KM7:TR?=	MWDTRW5ITVJ?
S-117	M3fCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTd3Lke1OUDPxE1?	NW[4cVc3W0GQR1XS
HuO9	M1e1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHSZ4hKSzVyPUe2MlAxPDhizszN	M2LwV3NCVkeHUh?=
CAL-51	Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITNOHpKSzVyPUe2MlExODZizszN	M3vkVHNCVkeHUh?=
BT-20	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2[3[GlEPTB;N{[uNlE3QCEQvF2=	MYHTRW5ITVJ?
LB831-BLC	NIjLNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XBXmlEPTB;N{[uN\|IyPyEQvF2=	NUX6fmZXW0GQR1XS
LB1047-RCC	MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfQTWM2OD15Nj63OlE6KM7:TR?=	NWr1N2FsW0GQR1XS
ES8	M{jTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{SxSmlEPTB;N{iuNFA4OyEQvF2=	MoLvV2FPT0WU
UMC-11	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2L1cGlEPTB;N{iuNFg5PCEQvF2=	M1;tU3NCVkeHUh?=
NCI-H226	NVfmVHViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2S1WWlEPTB;N{iuNVMyPSEQvF2=	MnvRV2FPT0WU
IGROV-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTd6LkW1OUDPxE1?	MWfTRW5ITVJ?
BHY	MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUC2RW9MUUN3ME23PU42QTZizszN	NYDLeWRrW0GQR1XS
MKN45	M1nhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLuTWM2OD16MD6zNVc1KM7:TR?=	Mn6wV2FPT0WU
IA-LM	NHexcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;0VmlEPTB;OECuN\|UyOSEQvF2=	MUTTRW5ITVJ?
WM-115	NIP6UotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRThzLkSxNVQh\|ryP	MmjRV2FPT0WU
VMRC-RCZ	MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jvc2lEPTB;OEGuOFQzPSEQvF2=	NHXIOplUSU6JRWK=
NCI-H2291	NGHPeJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\0[nZ6UUN3ME24NU43QDR{IN88US=>	NF[zSYpUSU6JRWK=
MCF7	MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LXbmlEPTB;OEOuNlg6PyEQvF2=	MYrTRW5ITVJ?
639-V	NVfRR\|I5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTrS2dYUUN3ME24OE43OTJ7IN88US=>	MVHTRW5ITVJ?
RT4	M2exOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T2eWlEPTB;OEWuNlQxOyEQvF2=	M{C2O3NCVkeHUh?=
NCI-H2405	NUiwZm5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33KbGlEPTB;OEWuNlk6PyEQvF2=	M3SwOnNCVkeHUh?=
CAL-33	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIr6d2pKSzVyPUi1MlY{OTVizszN	M3fHenNCVkeHUh?=
BT-549	MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLiTWM2OD16NT65N\|gzKM7:TR?=	M2HSc3NCVkeHUh?=
HT-1197	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnwbVBKSzVyPUi4MlExPzdizszN	MUDTRW5ITVJ?
G-361	NXz2RmpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEH6VHNKSzVyPUi4MlE1PzRizszN	MoKzV2FPT0WU
LS-411N	M1Ht[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrHPIZKSzVyPUi5MlM{QDhizszN	M{\nR3NCVkeHUh?=
HT-144	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVr6bFA5UUN3ME24PU42QTl{IN88US=>	M4DJRXNCVkeHUh?=
DJM-1	NVXxS45xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnBSWhKSzVyPUi5Mlg5PDVizszN	NEfYb5VUSU6JRWK=
CAL-12T	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fUXGlEPTB;OUCuO\|g6PSEQvF2=	MmPpV2FPT0WU
MKN7	M4n5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfPcI5KSzVyPUmxMlM2PTFizszN	NEjRTZhUSU6JRWK=
HuP-T3	MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nmeGlEPTB;OU[uNVAxPCEQvF2=	M2HyfnNCVkeHUh?=
SK-MG-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fWV2lEPTB;OU[uNVM1QCEQvF2=	Ml3mV2FPT0WU
NCI-H2347	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPkTZRMUUN3ME25PE4yODR{IN88US=>	NULrOYRxW0GQR1XS
SW872	NF3PRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTFyMD60OVYh\|ryP	MXjTRW5ITVJ?
COLO-829	NWXINohGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvDWnVKSzVyPUGwNE42PTNizszN	NGG0UnhUSU6JRWK=
MC-IXC	M3T2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVn1NVBNUUN3ME2xNFAvPjF3IN88US=>	NH33XVRUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; PubMed: 28626016 J Neurosci Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times. p-mTOR / mTOR / p-p70S6K / p70S6K ; PubMed: 30423811 Int J Mol Sci As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.	28626016 30423811
Growth inhibition assay	Cell viability; PubMed: 30423811 Int J Mol Sci Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, p < 0.01, and * p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red and * for SCC-4 and blue , * and *** for SCC-25).	30423811

Protocol

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-4708671 SDF

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?
Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

LY2584702 ^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate ^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671

Cited by 13 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-4708671 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671

Cited by 13 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PF-4708671 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)